Ameriprise Financial Inc. acquired a new stake in Insulet Co. (NASDAQ:PODD) in the third quarter, HoldingsChannel reports. The fund acquired 26,507 shares of the medical instruments supplier’s stock, valued at approximately $1,460,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Insulet by 11.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after purchasing an additional 235 shares during the period. SG Americas Securities LLC acquired a new position in Insulet in the second quarter valued at about $180,000. RNC Capital Management LLC acquired a new position in Insulet in the second quarter valued at about $225,000. Amalgamated Bank lifted its position in Insulet by 5.7% in the second quarter. Amalgamated Bank now owns 7,476 shares of the medical instruments supplier’s stock valued at $384,000 after buying an additional 406 shares during the last quarter. Finally, Strs Ohio lifted its position in Insulet by 29.6% in the third quarter. Strs Ohio now owns 7,000 shares of the medical instruments supplier’s stock valued at $385,000 after buying an additional 1,600 shares during the last quarter.

Shares of Insulet Co. (NASDAQ:PODD) opened at $75.08 on Wednesday. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65. The company has a market capitalization of $4,550.00, a PE ratio of -150.16 and a beta of 1.58. Insulet Co. has a fifty-two week low of $38.19 and a fifty-two week high of $78.65.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.06. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The company had revenue of $121.80 million during the quarter, compared to analysts’ expectations of $114.02 million. During the same quarter in the previous year, the business earned ($0.05) EPS. The firm’s revenue was up 28.4% on a year-over-year basis. equities research analysts forecast that Insulet Co. will post -0.43 earnings per share for the current fiscal year.

In other news, Director James C. Mullen bought 2,500 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was acquired at an average price of $67.45 per share, for a total transaction of $168,625.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.60% of the stock is currently owned by insiders.

A number of research firms have commented on PODD. Zacks Investment Research cut shares of Insulet from a “hold” rating to a “sell” rating in a research report on Tuesday. Morgan Stanley lifted their price objective on Insulet from $55.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Barclays initiated coverage on Insulet in a research report on Friday, September 15th. They set an “overweight” rating and a $65.00 price objective for the company. UBS Group upgraded Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday. Finally, Leerink Swann reiterated an “outperform” rating and set a $74.00 price objective (up previously from $65.00) on shares of Insulet in a research report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. Insulet has a consensus rating of “Buy” and a consensus price target of $62.53.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/ameriprise-financial-inc-takes-position-in-insulet-co-podd/1800933.html.

Insulet Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.